Anika Therapeutics Inc logo

Anika Therapeutics Inc(ANIK)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$12.92
11/16/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ANIK

11/16/2026: ANIK (1-star) is currently NOT-A-BUY. Pass it for now.

Anika Therapeutics is a medical specialty company that develops proprietary hyaluronic acid-based products for osteoarthritis pain management and joint preservation. The company's primary strengths lie in its established viscosupplement portfolio—such as Monovisc and Orthovisc—and strong commercial distribution partnerships. Its main growth opportunity involves expanding the adoption of advanced combination therapies like Cingal in international markets. However, the business faces risks related to product concentration, intensive competition from large medical device conglomerates, and regulatory execution. The stock may best suit growth or specialty healthcare investors who monitor clinical pipeline milestones and core product adoption trends.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitRevenue growth has historically been modest and incremental rather than rapid.
Momentum investorStrong fit while signal remains positiveMomentum fit is conditional on a positive Upturn signal and short-term price momentum breakout.
Value investorMixed fitValuation reflects niche medical positioning, but intermittent profitability metrics warrant careful review.
Dividend investorWeak fitThe company does not pay a dividend, prioritizing internal reinvestment instead.
Low-risk investorWeak fitSmall-cap biotechnology and medical device stocks experience regulatory and clinical trial volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highSmall-cap healthcare equities can experience sharp price swings based on clinical or earnings news.
Valuation riskMediumValuations are closely tied to execution on core product growth and pipeline milestones.
Competition risk (Orthopedic conglomerates)HighAnika competes with massive global medical device manufacturers possessing extensive distribution networks.
Business qualityMediumProprietary HA technology provides defensibility, though product concentration remains a factor.
Dividend incomeLow / noneNo cash dividends are distributed to shareholders.
Execution riskMedium / highSuccess depends heavily on commercial execution, regulatory approvals, and international expansion.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 179.50M USD
Price to earnings Ratio -
1Y Target Price 20
Price to earnings Ratio -
1Y Target Price 20
Volume (30-day avg) 117.5K shares
Beta 0.2
52 Weeks Range 9.01 - 22.88
Updated Date 11/15/2026
52 Weeks Range 9.01 - 22.88
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.03

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.7%
Active BUY / eligible
69 / 110
30-Day BUY Count Change
+30
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -20.18%
Avg. Invested days 43
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/16/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ANIK receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ANIK has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and strong ownership. In FY2025 versus FY2024, strong earnings growth (+80.7%) is partially offset by soft cash generation (FCF margin 3.9%), negative revenue growth (-5.9%), weak profitability (net margin -9.6%).

Financial Health Rating

★★★★★
ANIK's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 42.8%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ANIK's strongest growth driver at +287.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, earnings growth (+80.7%, strong) is also strong, while revenue growth (-5.9%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 93.1% and approximately 84.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 7.04% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 10.82%
Caligan Partners LP 10.71%
Morgan Stanley - Brokerage Accounts 4.59%
Acadian Asset Management LLC 4.53%
Vanguard Capital Management, LLC 4.27%

Unit Economics (Per $1K Revenue)

★★★★★
ANIK generates approximately $566 of gross profit, $-98 of operating income, and $39 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -7.22% (Tax Credit)

Quantitative Style Profile

★★★★★
ANIK has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Osteoarthritis Pain ManagementSales of single- and multi-injection viscosupplements including Monovisc, Orthovisc, and Cingal.This is Anika's primary profit driver, generating steady recurring revenue through global distribution partnerships.
Joint Preservation and RestorationBone-sparing joint technology products, implants, and sports medicine offerings.Complements the pain management portfolio by providing surgical solutions for joint care.
Geographic Markets (United States & International)Direct and distributor-led product sales spanning the U.S., Europe, and international markets.The United States constitutes the majority of sales, with Europe and other international markets providing secondary growth.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-06
When Before Market
Estimate 0.02
Actual -0.01

Profitability

Profit Margin -1.43%
Operating Margin (TTM) -0.09%

Management Effectiveness

Return on Assets (TTM) -0.04%
Return on Equity (TTM) -0.18%

Valuation

Trailing PE -
Forward PE 13.39
Enterprise Value 160.42M
Price to Sales(TTM) 1.45
Enterprise Value 160.42M
Price to Sales(TTM) 1.45
Enterprise Value to Revenue 1.3
Enterprise Value to EBITDA 52.27
Shares Outstanding 13.40M
Shares Floating 11.30M
Shares Outstanding 13.40M
Shares Floating 11.30M
Percent Insiders 7.04
Percent Institutions 93.12

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.